TrialCancer medicine2023

A multicenter, phase II trial of GC1118, a novel anti-EGFR antibody, for recurrent glioblastoma patients with EGFR amplification.

Seung Won Choi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.